NASDAQ:IMUX
Immunic Inc. Stock News
$1.29
+0.0450 (+3.61%)
At Close: May 20, 2024
Immunic, Inc. (IMUX) Q4 2022 Earnings Call Transcript
02:59pm, Thursday, 23'rd Feb 2023
Immunic, Inc. (NASDAQ:IMUX ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Jessica Breu - Head, IR & Communications Daniel Vitt - CEO, President & Director Glenn W
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
06:30am, Thursday, 16'th Feb 2023
– Webcast to be Held at 8:00 am ET on February 23, 2023 – NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline
Immunic: Multiple Sclerosis Data In H2 2023 Could Provide Major Shift
07:22am, Tuesday, 07'th Feb 2023
Interim results from the phase 2 CALLIPER study using IMU-838 for treatment of patients with Progressive MS are expected in the 2nd half of 2023; topline results are end of 2024. Final results from th
Immunic to Participate in Scientific and Investor Conferences in February
06:30am, Wednesday, 25'th Jan 2023
NEW YORK , Jan. 25, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chron
Immunic, Inc. (IMUX) Q3 2022 Earnings Call Transcript
01:55am, Sunday, 06'th Nov 2022
Immunic, Inc. (NASDAQ:IMUX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Jessica Breu - Head, IR and Communications Daniel Vitt - CEO and President Glenn Whaley -
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
06:30am, Thursday, 27'th Oct 2022
– Webcast to be Held at 8:00 am ET on November 3, 2022 – NEW YORK , Oct. 27, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline o
Steven Cohen's Firm Boosts Stakes in Relmada and Immunic
05:52pm, Tuesday, 25'th Oct 2022
Steven Cohen (Trades, Portfolio), chairman and CEO of Point72 Asset Management, disclosed in regulatory filings that his firm established a position in Progress Acquistion Corp. ( PGRWU , Financial) a
Why Is Immunic (IMUX) Stock Down 76% Today?
10:33am, Friday, 21'st Oct 2022
Immunic (NASDAQ: IMUX ) stock is plummeting on Friday after the company reported a high placebo rate in a Phase 1b clinical trial. This trial is currently ongoing and is testing the effectiveness of I
Immunic: New MS Drugs Need Extreme Product Differentiation
04:43pm, Wednesday, 12'th Oct 2022
The MS market is highly saturated. Although there's a lot of lacunae, new MS drugs need to show exactly why they should exist.
Immunic, Inc. to Participate in Investor Conferences in September
06:30am, Thursday, 01'st Sep 2022
NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chr
Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2022 Results - Earnings Call Transcript
01:32pm, Saturday, 06'th Aug 2022
Immunic, Inc. (NASDAQ:IMUX ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Jessica Breu - Head, Investor Relations and Communications Daniel Vitt - Chief Executive Of
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
06:30am, Thursday, 28'th Jul 2022
– Webcast to be Held at 8:00 am ET on August 4, 2022 – NEW YORK , July 28, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of s
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
06:30am, Wednesday, 08'th Jun 2022
NEW YORK , June 8, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chro
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
12:03pm, Friday, 03'rd Jun 2022
Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.
Why is Immunic (IMUX) Stock Plunging 40% Today?
01:03pm, Thursday, 02'nd Jun 2022
Immunic (IMUX) stock is falling hard on Thursday after the company released poor results from a recent Phase 2 clinical trial. The post Why is Immunic (IMUX) Stock Plunging 40% Today?